Gilead Sciences Company Profile (NASDAQ:GILD)

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 7 Hold Rating(s), 20 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $115.50 (33.44% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetActions
7/15/2016Jefferies GroupReiterated RatingHold$97.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2016Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/5/2016Cowen and CompanyReiterated RatingOutperform$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Credit Suisse Group AGReiterated RatingBuy$120.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Leerink SwannReiterated RatingOutperform$127.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016BMO Capital MarketsReiterated RatingOutperform$97.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Morgan StanleyReiterated RatingHold$103.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Robert W. BairdReiterated RatingOutperform$135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016GabelliInitiated CoverageBuy$109.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Citigroup Inc.Reiterated RatingBuy$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$120.00 -> $116.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/10/2016MizuhoReiterated RatingBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Bank of America Corp.Reiterated RatingNeutral$104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$91.00 -> $87.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Evercore ISIReiterated RatingBuy$115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016S&P Equity ResearchInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Barclays PLCLower Price TargetOverweight$130.00 -> $115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/1/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Needham & Company LLCReiterated RatingBuy$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/18/2015ArgusReiterated RatingBuy$150.00 -> $125.39View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2015Jyske BankUpgradeStrong-Buy$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Stifel NicolausDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015Nomura Holdings Inc.Set Price TargetBuy$141.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014Edward JonesInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014FBR & CoBoost Price TargetOutperform$125.00 -> $130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/25/2016Q216$3.01$7.80 billionListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$2.32$2.94$6.81 billion$7.59 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2015Q414$2.19$2.43$6.68 million$7.31 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014Q214$1.73$2.36$5.68 billion$6.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/22/2014Q114$0.85$1.48$3.80 billion$5.00 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2012$0.94$1.00ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$0.95$0.99ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.94$0.91ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$1.04$0.97ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$1.01$1.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/20/2011$0.97$0.87ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/25/2011$0.95$0.95ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$2.88$3.29$3.06
Q2 20162$3.03$3.25$3.14
Q3 20162$3.04$3.16$3.10
Q4 20162$3.53$3.87$3.70
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Annual Dividend:$1.88
Dividend Yield:2.17%
Payout Ratio:16.08% (Based on Trailing 12 Months of Earnings)
15.80% (Based on Current Year Consensus EPS Estimate)
14.64% (Based on Next Year Consensus EPS Estimate)

Dividend History for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Gilead Sciences (NASDAQ:GILD)
DateHeadline
07/22/16 04:09 PMIs Gilead Sciences, Inc. Stock A Buy Ahead Of Second Quarter Earnings - Amigobulls
07/22/16 04:09 PMCompany Update (NASDAQ:GILD): Gilead Sciences, Inc. Receives Positive CHMP Opinion for Approval of Truvada for ... - Smarter Analyst
07/22/16 04:09 PMHC Stocks Outlines: Gilead Sciences, Inc. (NASDAQ:GILD), Community Health Systems (NYSE:CYH) - share market updates (press release)
07/22/16 07:07 AMStocks Intraday Alert: Gilead Sciences Inc. (GILD), Aetna Inc. (AET), Halliburton Company (HAL) - iStreetWire
07/22/16 07:07 AMBuy Gilead: 4 Reasons Why - Seeking Alpha
07/22/16 07:07 AMTime To Put On The Watch List? - Gilead Sciences Inc. (NASDAQ:GILD), Heat Biologics, Inc. (NASDAQ:HTBX) - The Voice Registrar
07/22/16 06:19 AM7:19 am Gilead Sciences announces that the CHMP of the EMA has adopted a positive opinion on Type II variation application for once-daily Truvada in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infectio -
07/22/16 06:17 AMEuropean CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV - [Business Wire] - Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company’s Type II variation application for once-daily Truvada® in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy ...
07/21/16 05:38 PMGilead (GILD) Stock Likely to Beat This Earnings Season -
07/21/16 04:24 PMWhy Gilead Sciences (GILD) Might Surprise This Earnings Season
07/21/16 04:24 PMGilead Sciences : Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
07/21/16 03:30 PMGilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies - [Business Wire] - Gilead Sciences, Inc. today announced that two Phase 3b switch studies evaluating Odefsey® for the treatment of HIV-1 infection met their primary objectives.
07/21/16 01:46 PMWhy a low-price generic of this HIV drug may not hit the U.S. market soon - Gilead Sciences Inc. is asking a federal court to stop another drug maker from selling a lower-priced generic version of a blockbuster HIV-fighting drug in the United States. But the story goes beyond a relatively straightforward patent infringement suit between Foster City-based Gilead (NASDAQ: GILD) and Aurobindo Pharma Ltd. It is a case of Aurobindo apparently biting the proverbial hand that fed the Indian drug maker everything it needed to make the drug for AIDS patients in poor and developing…
07/21/16 11:19 AMGilead Sciences, Inc.: 2 GILD Stock Trades for Earnings - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips GILD stock looks to breakout of a long-term decline following Gilead Sciences' earnings report ... market willing The post Gilead Sciences, Inc.: 2 GILD Stock Trades for Earnings appeared first on InvestorPlace.
07/21/16 10:33 AM3 Enormously Important Things You Won't See in Gilead Sciences' Q2 Results - These are the critical items investors should care about that won't be obvious in this big biotech's Q2 results.
07/20/16 05:37 PMUpdate on Gilead Sciences Inc. (NASDAQ:GILD) for the day - Twin County News
07/20/16 05:37 PMIntraday Active Biotech Stocks News: Biogen Inc. (NASDAQ:BIIB), Gilead Sciences Inc. (NASDAQ:GILD) - The Voice Registrar
07/20/16 05:37 PMStock Analysis review: Gilead Sciences Inc. (NASDAQ:GILD) - News Oracle
07/20/16 05:37 PMWhy Gilead Sciences (GILD) Might Surprise This Earnings Season - Nasdaq
07/20/16 03:31 PMBetter Buy: Gilead Sciences Inc. vs. Amgen Inc. - In the battle of the big biotech stocks, how do Gilead and Amgen stack up against each other?
07/19/16 04:05 PMEarnings Estimates for These 3 Biotech Giants Should Be Heading Lower -- Here's Why - EPS estimates for Gilead Sciences, Alexion Pharmaceuticals, and BioMarin Pharmaceutical could be cut, but that's not a reason for investors to worry.
07/19/16 10:21 AMiShares Edge MSCI USA Quality Factor ETF Experiences Big Inflow
07/19/16 10:21 AMGilead Sciences to Release Second Quarter 2016 Financial Results on Monday ...
07/19/16 10:21 AMCutler Group Lp buys $18367479 stake in Gilead Sciences (GILD)
07/18/16 04:00 PMGilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016 - [Business Wire] - Gilead Sciences, Inc. announced today that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2016 and provide a general business update.
07/18/16 09:04 AMIs This Gilead Sciences' Most Underappreciated Drug Candidate? -
07/16/16 07:36 AMBest stocks of the day: Gilead Sciences Inc. (NASDAQ:GILD)
07/15/16 11:01 PM[$$] Balm for Gilead -
07/15/16 04:36 PMAn Unfair Valuation Makes a Great Investment -
07/15/16 03:13 PMStocks Highlights: Gerdau S.A. (GGB), Gilead Sciences Inc. (GILD), Banco Santander, S.A. (SAN) - iStreetWire
07/15/16 09:36 AMGilead's HCV Drug Epclusa Gets Regulatory Nod in Canada -
07/15/16 05:38 AMSpeech at the 114th Annual General Meeting of DMG MORI AKTIENGESELLSCHAFT on 15 July 2016 - [at noodls] - July 15, 2016 Check against delivery Dear Shareholders, Ladies and gentlemen, on behalf of the Executive Board, I would now also like to warmly welcome you to our 114 Annual General Meeting in Bielefeld. ...
07/14/16 04:22 PMGilead Sciences, Inc. (NASDAQ:GILD) Wins HIV Patent Manipulation Suit, But Case Awaits Appeal
07/14/16 04:22 PMCompany Update (NASDAQ:GILD): Gilead
07/14/16 10:01 AMHow Much Do Stock Prices Matter in Biotech? - The Industry Focus team compares Biogen's and Celgene's current valuations and considers what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.
07/14/16 06:30 AMGilead receives approval in Canada for EPCLUSA™ (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C - [PR Newswire] - -- 12-Week Treatment with EPCLUSA Provides High Cure Rates (SVR12) For All Six Hepatitis C Genotypes -- MISSISSAUGA, ON, July 14, 2016 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) has received ...
07/13/16 04:35 PMPrice Target Update: Gilead Sciences Inc. (NASDAQ:GILD) - News Oracle
07/13/16 04:35 PMGilead Sciences, Inc. Stock Is Set To Recover 2015 Highs Shortly - Amigobulls
07/13/16 07:04 AMNoticeable Buzzers: Gilead Sciences, Inc. (NASDAQ:GILD) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Street Updates
07/13/16 07:04 AMValeant Pharmaceuticals Intl Inc (VRX) Vs. Gilead Sciences, Inc. (GILD): Technical Analysis - TCC
07/13/16 05:40 AMJudge rules against AIDS patient advocates in Gilead lawsuit - A federal judge has ruled that pharmaceutical giant Gilead Sciences did not illegally manipulate the U.S. patent system by waiting years to introduce a less-toxic version of one of the world’s most-prescribed HIV medicines. The Los Angeles-based AIDS Healthcare Foundation had sued Gilead in January,...
07/12/16 03:17 PMFinding value in the rally -
07/12/16 02:43 PMGilead Sciences' Latest Approval Is a Big Deal - Epclusa may be the biggest advance in hepatitis C in two years, but does its approval pose risks to Gilead Sciences' existing hepatitis C franchise?
07/11/16 12:50 PMTop 7 Research Reports for July 11, 2016 -
07/11/16 08:57 AMGilead Sciences Inc. (NASDAQ:GILD) Achieves One More Milestone; Receives Marketing Authorization for Epclusa ... - Seneca Globe
07/10/16 08:39 AMPrice Target Review and Earnings Check on Gilead Sciences, Inc. (NASDAQ:GILD) - Press Telegraph
07/09/16 03:54 PMGilead Sciences Inc (GILD) President and CEO John F Milligan Sold $9.4 million of Stocks
07/09/16 07:43 AMCompany Update (NASDAQ:GILD): Gilead Sciences, Inc. Announces European Commission Approval of Epclusa for ... - Smarter Analyst
07/08/16 04:14 PMEuropean Commission Grants Marketing Authorization for Gilead's …
07/08/16 04:14 PMGilead's (GILD) Epclusa Granted EC Marketing Authorization as HCV Genotype 1-6 Treatment

Social

About Gilead Sciences

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $86.55
  • 50 Day Moving Average: $84.67
  • 200 Day Moving Average: $89.10
  • P/E Ratio: 7.39
  • P/E Growth: 9.19
  • Market Cap: $115.27B
  • Beta: 1.09
  • Current Year EPS Consensus Estimate: $11.9 EPS
  • Next Year EPS Consensus Estimate: $12.84 EPS
Additional Links:
Gilead Sciences (NASDAQ:GILD) Chart for Saturday, July, 23, 2016